Granted Patent
B2
US 12,479,807 · App. 17/712,001 · Granted Nov 25, 2025
Methods using HDAC11 inhibitors
Inventors:
Jennifer Lee (Arlington, MA); Nicholas Barczak (Waterford, CT); Jaime A. Escobedo (Natick, MA); Chiara Conti (Belmont, MA); Bingsong Han (Westwood, MA); David R. Lancia, Jr. (Boston, MA); Cuixian Liu (Madison, CT); Matthew W. Martin (Arlington, MA); Pui Yee Ng (Lexington, MA); Aleksandra Rudnitskaya (Roslindale, MA); Jennifer R. Thomason (Clinton, MA); Xiaozhang Zheng (Lexington, MA)
Assignee:
VALO HEALTH, INC.
C07D263/58A61K31/403A61K31/404A61K31/4184A61K31/4188A61K31/422A61K31/423A61K31/427A61K31/428A61K31/435A61K31/437A61K31/4439A61K31/4985A61K31/506A61K31/5377A61K31/5383A61K45/06A61P35/00C07C53/06C07D209/40C07D235/30C07D277/82C07D401/04C07D401/06C07D401/14C07D403/04C07D403/06C07D405/04C07D413/06C07D413/12C07D413/14C07D417/06C07D487/04C07D491/056C07D491/107C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
Claims (3)
1 . A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically accepted carrier.
Assignments (6)
RELEASE OF SECURITY INTEREST
Recorded Oct 17, 2023
From: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
To: VALO HEALTH, INC.; VALO HEALTH, LLC
Reel/Frame 065255/0660 →
SECURITY INTEREST
Recorded Jul 6, 2023
From: VALO HEALTH, LLC; VALO HEALTH, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Reel/Frame 064207/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 5, 2022
From: LEE, JENNIFER; BARCZAK, NICHOLAS; CONTI, CHIARA; ESCOBEDO, JAIME A.; HAN, BINGSONG; LANCIA, DAVID R., JR.; LIU, CUIXIAN; MARTIN, MATTHEW W.; NG, PUI YEE; RUDNITSKAYA, ALEKSANDRA; THOMASON, JENNIFER R.; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 060395/0311 →
MERGER
Recorded Jul 5, 2022
From: VALO EARLY DISCOVERY, INC.
To: VALO HEALTH, INC.
Reel/Frame 060395/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 5, 2022
From: FORMA THERAPEUTICS, INC.
To: INTEGRAL EARLY DISCOVERY, INC.
Reel/Frame 060572/0903 →
CHANGE OF NAME
Recorded Jul 5, 2022
From: INTEGRAL EARLY DISCOVERY, INC.
To: VALO EARLY DISCOVERY, INC.
Reel/Frame 060574/0585 →
Continuity (7)
Provisional Application
62410767
· Oct 20, 2016
Provisional Application
62410768
· Oct 20, 2016
Provisional Application
62410766
· Oct 20, 2016
References Cited (67)
US 9186318B2
· Yun et al.
· 2015
[cited by applicant]
US 9637453B2
· Ng et al.
· 2017
[cited by applicant]
US 20050159347A1
· DiMartino
· 2005
[cited by applicant]
US 20110160399A1
· Nagase et al.
· 2011
[cited by applicant]
US 20110237663A1
· Mascagni et al.
· 2011
[cited by applicant]
US 20140045850A1
· Mallais et al.
· 2014
[cited by applicant]
US 20150359794A1
· Benz et al.
· 2015
[cited by applicant]
US 20160222026A1
· Deziel et al.
· 2016
[cited by applicant]
US 20180127386A1
· Lee et al.
· 2018
[cited by applicant]
US 20190119364A1
· McKinsey et al.
· 2019
[cited by applicant]
US 20190270733A1
· Ma et al.
· 2019
[cited by applicant]
CN 103755595A
· 2014
[cited by applicant]
CN 105131082A
· 2015
[cited by applicant]
EP 3950677A1
· 2022
[cited by applicant]
WO WO0112630A1
· 2001
[cited by examiner]
WO WO2005066151A2
· 2005
[cited by applicant]
WO WO2005071079A1
· 2005
[cited by applicant]
WO WO2007038073A2
· 2007
[cited by applicant]
WO WO2009112550A1
· 2009
[cited by applicant]
WO WO2010034693A1
· 2010
[cited by applicant]
WO WO2014096386A1
· 2014
[cited by applicant]
WO WO2015106272A1
· 2015
[cited by applicant]
WO WO2015188015A1
· 2015
[cited by applicant]
WO WO2018075959A1
· 2018
[cited by applicant]
WO WO2018177126A1
· 2018
[cited by applicant]
WO WO2019204550A1
· 2019
[cited by applicant]
WO WO2020200160A1
· 2020
[cited by applicant]
WO WO2020232399A1
· 2020
[cited by applicant]
WO WO2021195598A1
· 2021
[cited by applicant]
Verstovsek, Srdan, Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636-642 (Year: 2009).
[cited by examiner]
Rubin et al. Nature Reviews Drug Discovery vol. 5, pp. 1026-1033 (2006) (Year: 2006).
[cited by examiner]
Upadhye et al., Rimcazole—A Sigma Receptor Antagonist—As a Potential Novel Therapy for Acute Myeloid Leukemia and Myeloma. vol. 106, Issue 11, Nov. 16, 2005, p. 2486 (Year: 2005).
[cited by examiner]
Jordan, CT, Unique molecular and cellular features of acute myelogenous leukemia stem cells, Leukemia (2002) 16, 559-562) (Year: 2002).
[cited by examiner]
American Cancer Society, Cancer Facts & Figures, 7 pages 2016. URL: www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf [Retrieved Aug. 2, 2018].
[cited by applicant]
Buglio, D. et al., HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma, Blood, 117(10): 2910-2917 (2011).
[cited by applicant]
Cheng, F. et al., Divergent Roles Of Histone Deacetylase 6 (HDAC6) and Histone Deacetylase 11 (HDAC11) on the Transcriptional Regulation of IL10 in Antigen Presenting Cells, Mol Immunol., 60(1):44-53 (2014).
[cited by applicant]
Deubzer, H. et al., HDAC11 is a novel drug target in carcinomas, Int J Cancer, 132(9): 2200-2208 (2013).
[cited by applicant]
Dokmanovic, M. et al., Histone Deacetylase Inhibitors: Overview and Perspectives, Mol Cancer Res., 981-989 (2007).
[cited by applicant]
Ganai, S. et al., Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance, Pharmaceutical Biology, 54(9): 1926-1935 …
[cited by applicant]
Gao, L. et al., Cloning and Functional Characterization of HDAC11, A Novel Member of the Human Histone Deacetylase Family, J Biol Chem., 277(28): 25748-25755 (2002).
[cited by applicant]
Gobert, M. et al., Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Res., 69: 2000-2009 …
[cited by applicant]
International Search Report for Ganai, S. et al., Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance, Pharmaceu…
[cited by applicant]
International Search Report for PCT/US2019/028026, 4 pages (mailed Aug. 8, 2019).
[cited by applicant]
Joshi, P. et al., The functional interactome landscape of the human histone deacetylase family, Molecular Systems Biology, 9(672): 1-21 (2013).
[cited by applicant]
Lozada, E.M. et al., Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer, Oncotarget, 7(15): 20425-20439 (2016).
[cited by applicant]
Martin, M.W et al., Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11, Bioorganic & Medicinal Chemistry Letters, 28(12): 2143-2147 (2018).
[cited by applicant]
Sahakian, E. et al., Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function, Mol Immunol., 63(2): 579-85 (2015).
[cited by applicant]
Sonbol, M.B. et al., Comprehensive review of JAK inhibitors in myeloproliferative neoplasms, Ther Adv Hematol., 4(1): 15-35 (2013).
[cited by applicant]
Villagra, A. et al., The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance, Nat Immunol., 10(1): 92-100 (2009).
[cited by applicant]
Watanabe, Y. et al., Dendrite Development Regulated by the Schizophrenia-Associated Gene FEZ1 Involves the Ubiquitin Proteasome System, Cell Rep., 7(2): 552-564 (2014).
[cited by applicant]
Weina, K. et al., SOX2 and cancer: current research and its implications in the clinic, Clin and Translational Med., 3(19): 1-10 (2014).
[cited by applicant]
Wong, et al., Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin, Cell Cycle., 9(21): 4351-63 (2010).
[cited by applicant]
Written Opinion for PCT/US2017/057715, 9 pages, ISA/US (mailed Feb. 12, 2018).
[cited by applicant]
Written Opinion for PCT/US2019/028026, 7 pages (mailed Aug. 8, 2019).
[cited by applicant]
Zdanov, S. et al., Mutant KRAS conversion of conventional T cells into regulatory T cells, Cancer Immunol Res., 38 pages (Feb. 15, 2016), URL: http://cancerimmunolres.aacrjournals.org/content/early/2016/02/13/2326-6066.…
[cited by applicant]